SMARCA4 and angiosarcoma: Best response was CR in one patient with cutaneous angiosarcoma (1%), PR in 14 patients (17%, 2 cutaneous KS, 2 cutaneous UPS/PDS and 2 UPS of other sites, 2 cutaneous angiosarcomas and 1 angiosarcoma of other site, 1 ASPS, 1 DDLS, 1 dermal fibrosarcoma, 1 pleomorphic rhabdomyosarcoma, and 1 SMARCA4-deficient thoracic sarcoma), SD in 13 patients (15%), and PD in 56 patients (67%).